Novel Analysis of the Oral Treprostinil Combination Therapy Trial Data

Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation

“…There is now recently published evidence supporting the group consensus around combination/second-line therapy. 26 …”

Novel dose–response analyses of treprostinil in pulmonary arterial hypertension and its effects on six‐minute walk distance and hospitalizations

“…Several post-hoc analyses suggest a dose-response relationship of oral treprostinil monotherapy in which higher doses correspond to greater improvements in functional capacity [31][32][33]. In another analysis of oral treprostinil used as combination therapy, White and colleagues found a significant difference in 6MWD change from baseline between the low and high dose groups at week 16 [34]. More recently, longer term dose-response findings in the FREEDOM-EV study were published showing that patients achieving ≥3 mg TID at week 24 had greater improvements in 6MWD, N-terminal pro-brain natriuretic peptide, WHO FC, and BDS compared to the <3 mg TID group while experiencing a similar rate of adverse events [35].…”

Long‐term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics

“…[11][12][13] All study procedures were approved by an independent institutional review board before investigators obtained written informed consent from each participant. We collected data from January 16,2007 to September 1, 2015. In order to make meaningful comparisons, the visit labeled 'Baseline' was prior to oral treprostinil exposure; for those assigned to active drug, this was the first day of the parent study, and for those initially assigned placebo, Baseline was the final visit of the parent study.…”